Shenzhen Beike Biotechnology Co., Ltd., a worldwide leader in providing safe and effective stem cell applications for medical treatment, has commenced outfitting its 21,500 square foot comprehensive medical stem cell storage and processing facility in eastern China. 

 

Jiangsu Stem Cell Storage facility will be one of the most highly developed of its kind anywhere in the world, with advanced technology and safe conditions to properly freeze, store, and process a broad range of human stem cell samples for clinical application. The stem cell storage facility will initially provide stem cell banking for human umbilical cord blood stem cells, placenta stem cells, amniotic membrane stem cells, bone marrow stem cells, and later will be able to house induced pluripotent stem cells (iPS).

The Stem Cell Storage Facility, which is set to be fully functional by year end 2008, is located next to the 15,000 square foot Jiangsu Beike Biotechnology office building, which already houses a showroom showcasing Beike's technologies and treatments. Beike ultimately plans for the entire facility to be able to house up to 100,000 stem cell samples.

Considered the future for stem cell treatments, iPS cells are derived from cell reprogramming technologies and are a non-controversial potential alternative to embryonic stem cells. Like umbilical cord blood stem cells, iPS cells can be preserved for later use in fighting a range of disorders.

A new, technologically advanced laboratory will occupy ten thousand square feet of the stem cell storage facility and will produce quality Beike stem cells for use in treating patients in the leading hospitals of China's Jiangsu Province and greater Shanghai regions. Beike's stem cells are already used nationally in some of China's leading hospitals to treat more than 200 patients per month suffering from a range of debilitating disorders like ataxia, brain injury, cerebral palsy, diabetic feet, lower limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury and optic nerve damage. 

This new central processing laboratory model supersedes Beike's prior need to build laboratories inside hospitals, meaning Beike treatments will become more affordable as stem cell component costs are reduced, fulfilling Beike's mission to improve the quality of life for as many patients as possible.